Aimee J. Lenar
CIK 2029927 · President, US Pharma · last filed 2026-08-20
Aimee J. Lenar is a President, US Pharma who has filed 9 SEC Form 4 insider transactions across 1 company since 2024. The most recent filing shows the insider sold $258.9K of BHC on Aug 20, 2026. Across all open-market trades the lifetime net is −$258.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions. 10 SEC filings were submitted jointly with Bausch Health Companies Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.89M
1
9
-$258.9K
Filer Profile
BRIDGEWATER, NJ 08807
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BHC | President, US Pharma | 334,853 | $5.64 | $1.89M | -$258.9K | 8 | 2026-08-20 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-20 | BHC | Sell (S) | −36,827 | -$258.9K | EDGAR |
| 2026-08-19 | BHC | Notice (144) | −36,827 | -$258.9K | EDGAR |
| 2026-07-20 | BHC | Tax (F) | −5,260 | -$25.4K | EDGAR |
| 2026-07-17 | BHC | Tax (F) | −23,395 | -$114.4K | EDGAR |
| 2026-02-27 | BHC | Mixed | +139,561 | -$106.2K | EDGAR |
| 2025-07-18 | BHC | Grant (A) | +30,847 | $0 | EDGAR |
| 2025-07-16 | BHC | Tax (F) | −22,736 | -$146.0K | EDGAR |
| 2025-02-28 | BHC | Grant (A) | +108,311 | $0 | EDGAR |
| 2024-07-17 | BHC | Grant (A) | +144,352 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.